Show simple item record

dc.contributor.authorChopra, R
dc.contributor.authorGoldstone, A H
dc.contributor.authorMcMillan, A K
dc.contributor.authorPowles, R
dc.contributor.authorSmith, A G
dc.contributor.authorPrentice, H G
dc.contributor.authorReid, C
dc.contributor.authorMarcus, R
dc.contributor.authorBell, A
dc.contributor.authorMilligan, D
dc.contributor.authorMorgenstern, Godfrey R
dc.contributor.authorBarnard, D
dc.date.accessioned2010-08-02T10:33:11Z
dc.date.available2010-08-02T10:33:11Z
dc.date.issued1991-10
dc.identifier.citationSuccessful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. 1991, 9 (10):1840-7 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid1919634
dc.identifier.urihttp://hdl.handle.net/10541/108803
dc.description.abstractThe results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis (four patients; one fatal), intracranial hemorrhage (two patients; two fatal) has occurred. There have been four procedure-related deaths (12%). Hematologic recovery was satisfactory for neutrophils (median time to 0.5 x 10(9)/L, 22 days [range, 11 to 101 days]), but very slow for platelets (median time to 50 x 10(9)/L, 62 days [range, 15 to 1,080 days]). This study suggests that the use of Bu/Cy with ABMT for patients beyond first remission in AML compares favorably with chemotherapy, and although the procedure-related mortality is acceptable, it is associated with protracted platelet recovery.
dc.language.isoenen
dc.subjectMyeloid Leukaemiaen
dc.subject.meshAcute Disease
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBone Marrow Transplantation
dc.subject.meshBusulfan
dc.subject.meshCombined Modality Therapy
dc.subject.meshCyclophosphamide
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRemission Induction
dc.subject.meshSurvival Analysis
dc.subject.meshTransplantation, Autologous
dc.titleSuccessful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.en
dc.typeArticleen
dc.contributor.departmentUniversity College and Middlesex Schools of Medicine, London, England.en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractThe results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis (four patients; one fatal), intracranial hemorrhage (two patients; two fatal) has occurred. There have been four procedure-related deaths (12%). Hematologic recovery was satisfactory for neutrophils (median time to 0.5 x 10(9)/L, 22 days [range, 11 to 101 days]), but very slow for platelets (median time to 50 x 10(9)/L, 62 days [range, 15 to 1,080 days]). This study suggests that the use of Bu/Cy with ABMT for patients beyond first remission in AML compares favorably with chemotherapy, and although the procedure-related mortality is acceptable, it is associated with protracted platelet recovery.


This item appears in the following Collection(s)

Show simple item record